Navigation Links
Genetically reprogrammed HSV given systemically shrinks distant sarcomas
Date:7/7/2010

CINCINNATI Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

Less than 30 percent of patients with metastatic cancer survive beyond five years, despite the aggressive use of modern combination therapies, including chemotherapy. This creates a significant need for new sarcoma therapies to treat metastatic disease, said Timothy Cripe, M.D., Ph.D., a physician/researcher in the division of Hematology/Oncology at Cincinnati Children's Hospital Medical Center and the study's senior investigator.

The study results are even more significant because the oncolytic herpes virus, HSV-rRp450, was given to the mice systemically to attack tumors via the blood stream instead of being injected directly into tumors.

"Systemic bio-distribution has been a major stumbling block for using virus vectors in gene transfer and virotherapy to treat cancer, but we show that viruses can be used systemically by giving them intravenously to get an anti-tumor effect," Dr. Cripe said.

Also important to results of the current study was using the virus in conjunction with a drug (bevacizumab) that blocks the growth of tumor feeding-blood vessels. In the current study, researchers focused on spreading Ewing sarcoma and Rhabdomyosarcoma cancers that form in muscle, bone and connective tissue.

Anti-angiogenic agents like bevacizumab are usually given first in combination cancer therapies because they help enlarge intercellular openings to tumor cells and ease the delivery of drugs, such as chemotherapies. In this study, however, the researchers discovered that bevacizumab has to be given after the virus to maximize the anti-tumor effect of the combined therapy. In fact, giving bevacizumab first lowered the virus's uptake in cancer cells.

The rRp450 oncolytic virus used in the study was derived from herpes simplex type 1. The virus was genetically modified by scientists by removing a gene that makes the virus unable to replicate efficiently in dormant cells. This causes the virus to selectively target and replicate in rapidly growing cancer cells while leaving normally dormant healthy tissue cells alone.

After removing the one gene from the virus, researchers replaced it with a gene that encodes an enzyme that activates a class of anti-tumor chemotherapies called oxazaphosphorines. The overall therapeutic approach is for the virus to infect and degrade the cancer cells and then activate chemotherapy agents as anti-angiogenic agents cut off vascular growth and blood supply to the tumors.

In the current study, however, researchers treated the mice only with rRp450 and the anti-angiogenic drug bevacizumab. This allowed them to test whether the virus could be given systemically, how anti-angiogenic drugs affected virus tumor uptake and the impact this had on tumor growth.

In mice receiving bevacizumab prior to the rRp450, overall tumor shrinkage averaged 40 percent. In mice receiving rRp450 before bevacizumab, tumor size was reduced by an average of 75 percent. The researchers also reported that mice treated with rRp450 before bevacizumab had longer survival rates.

Results of the current study could be used immediately to help design subsequent research into treatment protocols for oncolytic viruses, particularly clinical trials involving combination therapeutic strategies, Dr. Cripe said. Clinical trials are underway in the United States and Europe using oncolytic herpes viruses similar to the one used in the current study.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert  

Related biology news :

1. Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants
2. Researchers genetically link Lou Gehrigs disease in humans to dog disease
3. Scientists unlock possible aging secret in genetically altered fruit fly
4. Cats eye diseases genetically linked to diseases in humans
5. Origins of wolverine in California genetically verified
6. Weed resistance to glyphosate in genetically modified soybean cultivation in Argentina
7. Genetically corrected blood cells obtained from skin cells from Fanconi anemia patients
8. Genetically engineered mice yield clues to knocking out cancer
9. First genetically-engineered malaria vaccine to enter human trials
10. Genetically-modified mice reveal another mechanism contributing to heart failure
11. New study reveals first ever method to genetically identify all 8 tuna species
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetically reprogrammed HSV given systemically shrinks distant sarcomas
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... ... ... Studies indicate that replacing damaged brain cells with those derived from human embryonic ... not been determined is the optimal stage during differentiation of the stem cells that ... coming out of Singapore, recently published in STEM CELLS Translational Medicine journal may provide ...
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics announced today ... and fermentation process. The efficiencies created by the newest strain design will ... the ethanol industry wherein individual production plants are planning to invest upwards of ...
(Date:6/26/2017)... Philadelphia, PA (PRWEB) , ... June 26, 2017 , ... ... at its annual Shareholders Meeting on June 9, 2017: Jeremy Nowak, President, J Nowak ... The Science Center also announced the election of Glen N. Gaulton and Kenneth L. ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of ... the University Aviation Association (UAA), the unifying voice for collegiate aviation education, are ... encourage teamwork, competition, and success through a STEM-based education platform. , Much like ...
Breaking Biology Technology: